123 iodine Report issue

Small molecule Experimental
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
IODINE I-123 is a radioactive isotope of iodine used in nuclear medicine imaging, including single photon emission computed tomography (SPECT) and X-ray computed tomography (X-Ray CT) scans. Iodine-123 is usually supplied as sodium iodide (NaI) and hypoiodite (OI−) in dilute sodium hydroxide solution, at high isotopic purity. 123I is the most suitable isotope of iodine for the diagnostic study of thyroid diseases. The half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and 123I has other advantages for diagnostic imaging thyroid tissue and thyroid cancer metastasis. The iodine is taken up by the thyroid gland and/or cancer metastasis and a gamma camera is used to functional images of the thyroid for diagnosis. Quantitative measurements of the thyroid can be performed to calculate the iodine uptake (absorption) for the diagnosis of hyperthyroidism and hypothyroidism. This is administered to a patient in capsule form, by intravenous injection, or in a drink.   NCATS

Chemistry

  • SMILES: [123I][123I]
  • InChIKey: PNDPGZBMCMUPRI-UBRKOFTGSA-N
  • Mol. Mass: 245.811195888
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

123i− | 123 iodine | i123 | i 123 | i-123 | iodide i-123 | iodide ion i-123 | iodine 123 | iodine-123

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Thyroid Diseases (approved 1976)

Thyroid Neoplasms (approved 1991)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Thyroid Neoplasms (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue